Exosomes Implication in PD1-PD-L1 Activation in OSAS

Cancer Clinical Trial

— ExoSAS  

Official title:

Exosomes Implication in PD1-PD-L1 Pathway Activation in Obstructive Sleep Apnea Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03811600
• Other study ID #: 2019-A00029-48
• Status: Completed
• Start date: March 3, 2019
• Est. completion date: October 14, 2020

Study information

• Verified date: May 2022
• Source: University Hospital, Angers
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

An increased occurrence of cancer associated mortality has been described in patients with Obstructive Sleep Apnea Syndrome (OSAS). This association might be partially explained by an impaired cellular immune response that has been described in OSAS. Is has been suggested that OSAS impact immune cells by upregulation of the PD-1/PD-L1 pathway. Exosomes are small membrane vesicles released by numerous cells in the bloodstream. Exosomes have been shown to be implicated in cancer cells proliferation via a PD-1/PD-L1 pathway activation.

This study will evaluate exosomal PD-1/PD-L1 expression in patients with OSAS as compared to controls and will further investigate their impact on immune cells function and proliferation capacities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: October 14, 2020
• Est. primary completion date: October 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients requiring a sleep recording for suspected OSAS

Exclusion Criteria:

• Préviously treated OSAS

• Cancer past history

• Pregnant women

• Cognitif impairment

Related Conditions & MeSH terms

• Cancer
• Sleep Apnea Syndromes
• Sleep Apnea Syndromes, Obstructive
• Sleep Apnea, Obstructive
• Syndrome

Intervention

Diagnostic Test:
• PD1/PD-L1 exosomal expression
exosomal PD1/PD-L1 expression

Locations

Country	Name	City	State
France	Laboratoire du Sommeil, Département de Pneumologie, CHU d'Angers	Angers

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	exosomal PD1 expression	Peripheral blood (˜20 ml) will be collected from non-OSAS or OSAS subjects on EDTA-coated tubes. Exosomes will be isolated by centrifugation. For detecting exosome-associated surface proteins by flow cytometry, exosomes will be first captured on magnetic beads. The bead/exosome complexes will be then co-incubated with the labeled detection antibodies, either anti-PD1. Next, the complexes will be washed 3x resuspended in 300uL of PBS for antigen detection by flow cytometry.	at baseline
Primary	exosomal PD-L1 expression	Peripheral blood (˜20 ml) will be collected from non-OSAS or OSAS subjects on EDTA-coated tubes. Exosomes will be isolated by centrifugation. For detecting exosome-associated surface proteins by flow cytometry, exosomes will be first captured on magnetic beads. The bead/exosome complexes will be then co-incubated with the labeled detection antibodies, either anti-PD-L1. Next, the complexes will be washed 3x resuspended in 300uL of PBS for antigen detection by flow cytometry.	at baseline